MedTrace Logo

The Safety/Efficacy Study of Human Umbilical Cord Mesenchymal Stem Cells Therapy (19#iSCLife®-LDP) for Lumbar Discogenic Pain

NCT04104412 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 242

Last updated 2026-04-23

No results posted yet for this study

Summary

This experimental use umbilical cord mesenchymal stem cells in treatment of the early stage of lumbar discogenic pain (endogenous pain of the disc) to evaluate its safety and efficacy.

This experimental is mainly aimed at over 18years old people, regardless of gender, with refractory and persistent back pain for more than 6 months.

The efficacy and safety of mesenchymal stem cells (MSCS) were evaluated by low-temperature plasma ablation and intravertebral disc injection, which were divided into treatment group and control group.

Conditions

  • Lumbar Discogenic Pain

Interventions

BIOLOGICAL

human umbilical cord mesenchymal stem cell

2\*10\^7

Sponsors & Collaborators

  • Sclnow Biotechnology Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Yuanzhang Tang, Doctor · Xuanwu Hospital, Beijing

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-15
Primary Completion
2026-12-31
Completion
2027-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04104412 on ClinicalTrials.gov